Matthew Kowgier
0000-0003-4030-0924
Publication & Citation Trends
Publications
0 total
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trial.
Cited by 1
Semantic Scholar
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation
Cited by 2
Semantic Scholar
1117P Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial
Cited by 0
Semantic Scholar
Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.
Cited by 3
Semantic Scholar
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
Cited by 1
Semantic Scholar
LB001/#1593 Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib for endometrial cancer: mismatch repair deficient and/or microsatellite instability-high subpopulation efficacy analyses from the DUO-E trial
Cited by 0
Semantic Scholar
Research Topics
Hepatitis C virus research
(14)
Liver Disease Diagnosis and Treatment
(7)
Ovarian cancer diagnosis and treatment
(7)
Endometrial and Cervical Cancer Treatments
(7)
Genetic factors in colorectal cancer
(6)
Affiliations
Ontario Institute for Cancer Research
Roche (Switzerland)
Mount Sinai Hospital
University Health Network
3M (United States)